# A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

> **NCT05961111** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Yunying Medical Technology** · enrollment: 20 (estimated)

## Conditions studied

- Sarcoma
- Carcinoma
- Digestive Cancer
- Breast Cancer
- Lung Cancer
- Brain Cancer
- Melanoma
- Gynecologic Cancer
- Head and Neck Cancer
- Kidney Cancer

## Interventions

- **DRUG:** Recombinant oncolytic herpes simplex virus type 1 (R130)

## Key facts

- **NCT ID:** NCT05961111
- **Lead sponsor:** Shanghai Yunying Medical Technology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-24
- **Primary completion:** 2025-06
- **Final completion:** 2026-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05961111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05961111, "A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05961111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*